Tradestie Institutional Equity Comparison Engine

FEMY vs ICU โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FEMY Overall Edge

FEMY Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Femasys Inc. Common Stock (FEMY) driven by superior Momentum & Technical, Options & Structure while ICU counters with relative strength in Growth & Margin. Fundamentally, FEMY trades at N/M Forward P/E with -763.9% operating margin (-18.9% YoY revenue) versus ICU at N/M Forward P/E and -816.6% operating margin (+82.0% YoY). In options structure, FEMY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ICU sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
FEMY N/M vs ICU N/M Fwd P/E
Growth & Margin Winner ICU
Op Margin -763.9% vs -816.6% ยท YoY -18.9% vs +82.0%
Momentum & Technical Winner FEMY
1Y +54.8% vs +85.5% ยท 52W Pos 17% vs 12%
Options & Structure Winner FEMY
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
1M Return -22.42%
1Y Return +54.78%
Forward P/E N/M
Unified AI Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
ICU NASDAQ
SeaStar Medical Holding Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.85
+1.8% 1D
Market Cap $4.5M
1M Return -70.57%
1Y Return +85.5%
Forward P/E N/M
Unified AI Score
41.7 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FEMY +54.78% ICU +85.5% Spread: +30.72 pp (ICU Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period FEMY Revenue ICU Revenue FEMY Op. Margin ICU Op. Margin Margin Edge
FY2020 $0M N/A -668.0% N/A FEMY
FY2021 $0M N/A -706.7% N/A FEMY
FY2022 $0M N/A -961.7% N/A FEMY
FY2023 $0M N/A -1353.4% N/A FEMY
FY2024 $0M $0M -1091.8% -13216.3% FEMY
FY2025 $0M $0M -767.0% -986.6% FEMY

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FEMY (4) vs ICU (2)
Institutional Metric FEMY ICU Criterion Row Winner
Market Capitalization Scale $11.9M $4.5M Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -18.9% +82.0% Higher Growth ICU
Operating Margin (TTM) Profitability -763.9% -816.6% Higher Margin FEMY
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -425.0% -356.9% Higher ROE ICU
52-Week Range Position Momentum 17% ($0โ€“$6) 12% ($0โ€“$5) Stronger Trend FEMY
Beta / 30D Volatility Risk Regime 4.01ฮฒ ยท 72% Vol 1.35ฮฒ ยท 174% Vol Lower Realized Risk FEMY
Unified Institutional Score Composite Signal 52.6 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite FEMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FEMY vs ICU Buy Guide
FEMY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live FEMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ICU BREAKDOWN
133d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICU Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FEMY nor ICU registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.